165 related articles for article (PubMed ID: 6392368)
1. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses.
Ahmed AR; Hombal SM
J Am Acad Dermatol; 1984 Dec; 11(6):1115-26. PubMed ID: 6392368
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology and toxicology of cyclophosphamide: emphasis on use in rheumatic diseases.
Kovarsky J
Semin Arthritis Rheum; 1983 May; 12(4):359-72. PubMed ID: 6348951
[No Abstract] [Full Text] [Related]
3. Cyclophosphamide toxicity. Characterising and avoiding the problem.
Fraiser LH; Kanekal S; Kehrer JP
Drugs; 1991 Nov; 42(5):781-95. PubMed ID: 1723374
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive treatment of rheumatic diseases. Experimental bases of a rational concept of therapeutic approach (author's transl)].
Lemmel EM; Botzenhardt U
Arzneimittelforschung; 1976; 26(7):1281-95. PubMed ID: 1087561
[TBL] [Abstract][Full Text] [Related]
5. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis.
Plotz PH; Klippel JH; Decker JL; Grauman D; Wolff B; Brown BC; Rutt G
Ann Intern Med; 1979 Aug; 91(2):221-3. PubMed ID: 464465
[TBL] [Abstract][Full Text] [Related]
6. Therapeutics. XI. Immunosuppressive drugs.
Ashton H; Beveridge GW; Stevenson CJ
Br J Dermatol; 1970 Aug; 83(2):326-30. PubMed ID: 4916789
[No Abstract] [Full Text] [Related]
7. Immunosuppressive therapy in the rheumatic diseases.
Can Med Assoc J; 1971 Dec; 105(11):1125-6. PubMed ID: 4948506
[No Abstract] [Full Text] [Related]
8. Immunologic and clinical effects of cytotoxic drugs used in the treatment of rheumatoid arthritis and systemic lupus erythematosus.
Fox DA; McCune WJ
Concepts Immunopathol; 1989; 7():20-78. PubMed ID: 2676180
[No Abstract] [Full Text] [Related]
9. Mechanisms of in vitro immunosuppression by hepatocyte-generated cyclophosphamide metabolites and 4-hydroperoxycyclophosphamide.
Kawabata TT; Chapman MY; Kim DH; Stevens WD; Holsapple MP
Biochem Pharmacol; 1990 Sep; 40(5):927-35. PubMed ID: 2117927
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of 6-mercaptopurine and cyclophosphamide on autoimmune phenomena in NZB mice.
Lemmel E; Hurd ER; Ziff M
Clin Exp Immunol; 1971 Feb; 8(2):355-62. PubMed ID: 4102260
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
Berd D; Maguire HC; Mastrangelo MJ
Cancer Res; 1984 Nov; 44(11):5439-43. PubMed ID: 6488195
[TBL] [Abstract][Full Text] [Related]
12. Water intoxication induced by low-dose cyclophosphamide in two patients with systemic lupus erythematosus.
Salido M; Macarron P; Hernández-García C; D'Cruz DP; Khamashta MA; Hughes GR
Lupus; 2003; 12(8):636-9. PubMed ID: 12945725
[TBL] [Abstract][Full Text] [Related]
13. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
Fleming RA; Cruz JM; Webb CD; Kucera GL; Perry JJ; Hurd DD
Bone Marrow Transplant; 1996 Apr; 17(4):497-501. PubMed ID: 8722345
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies.
Drachman DA; Paterson PY; Schmidt RT; Spehlmann RF
J Neurol Neurosurg Psychiatry; 1975 Jun; 38(6):592-7. PubMed ID: 1097604
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Weiner HL; Cohen JA
Mult Scler; 2002 Apr; 8(2):142-54. PubMed ID: 11990872
[TBL] [Abstract][Full Text] [Related]
16. Antineoplastic and immunosuppressive drugs. 3. Adverse effects and therapeutic problems.
Cridland MD
Drugs; 1972; 3(5):352-65. PubMed ID: 4569065
[No Abstract] [Full Text] [Related]
17. Immunosuppressive agents in dermatology.
Ho VC; Zloty DM
Dermatol Clin; 1993 Jan; 11(1):73-85. PubMed ID: 8435920
[TBL] [Abstract][Full Text] [Related]
18. Hyperbaric oxygen therapy for cyclophosphamide-induced intractable refractory hemorrhagic cystitis in a systemic lupus erythematosus patient.
Jou YC; Lien FC; Cheng MC; Shen CH; Lin CT; Chen PC
J Chin Med Assoc; 2008 Apr; 71(4):218-20. PubMed ID: 18436507
[TBL] [Abstract][Full Text] [Related]
19. High dose cyclophosphamide therapy in solid tumors. Therapeutic, toxic, and immunosuppressive effects.
Mullins GM; Anderson PN; Santos GW
Cancer; 1975 Dec; 36(6):1950-8. PubMed ID: 128408
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of cyclophosphamide, isophosphamide, 4-methylcyclophosphamide, and phosphoramide mustard on murine hematopoietic and immunocompetent cells.
Sensenbrenner LL; Marini JJ; Colvin M
J Natl Cancer Inst; 1979 Apr; 62(4):975-81. PubMed ID: 285298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
